Turning the tables on surgical oncology: the • Pancho trial unplugged
| Autor: | Sebastian F. Schoppmann, Johannes Zacherl, S. Gacic, Martina Mittlböck, Brigitte Wolf, Irene Kührer, Christoph Bichler, Sonja Kappel, Gerald W. Prager, Yelena Devyatko, Ahmed Ba-Ssalamah, Ursula Pluschnig, Michael Hejna, Fritz Wrba, Daniela Kandioler |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Predictive marker business.industry medicine.medical_treatment General surgery Evidence-based medicine Vascular surgery Esophageal cancer medicine.disease law.invention Randomized controlled trial Surgical oncology law medicine Physical therapy Clinical endpoint Surgery business Neoadjuvant therapy |
| Zdroj: | European Surgery. 40:277-283 |
| ISSN: | 1682-4016 1682-8631 |
| DOI: | 10.1007/s10353-008-0438-5 |
| Popis: | BACKGROUND: In esophageal cancer patients neoadjuvant therapy failed to demonstrate a clear benefit in overall survival. A significant advantage can be seen in patients with complete pathological response. METHODS: This review summarizes the results of retrospective clinical studies suggesting p53 as a predictive marker for chemotherapy response. To advance these findings to level of evidence I the • Pancho trial was initiated. RESULTS: The • Pancho trial represents the first prospective randomized trial testing the interaction between p53 and response to chemotherapy. The special design of the • Pancho trial (interaction design), the sample size considerations, the study endpoints and the 12 months accrual of this nationwide study are reported. CONCLUSIONS: The • Pancho trial evaluates for the first time whether the p53 genotype is qualified to select patients who will respond to certain chemotherapy and to guide cancer therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|